Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 57.05B P/E 74.35 EPS this Y - Ern Qtrly Grth 49.80%
Income 229.1B Forward P/E - EPS next Y - 50D Avg Chg -6.00%
Sales 1.69T PEG - EPS past 5Y - 200D Avg Chg -9.00%
Dividend 98.00% Price/Book 0.04 EPS next 5Y - 52W High Chg -21.00%
Recommedations - Quick Ratio 2.04 Shares Outstanding 1.90B 52W Low Chg 19.00%
Insider Own - ROA 5.38% Shares Float 1.91B Beta 0.28
Inst Own 0.04% ROE 14.11% Shares Shorted/Prior -/- Price 29.74
Gross Margin 75.30% Profit Margin 13.58% Avg. Volume 250,850 Target Price -
Oper. Margin 21.32% Earnings Date Oct 28 Volume 88,171 Change -3.03%
About DAIICHI SANKYO COMPANY LIMITED

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications caused by bone metastasis from tumors; Tarlige for treating neuropathic pain; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for COVID-19 infection, influenza infection, adsorbed cell culture-derived influenza (H5N1), measles/rubella infection, and mumps. The company has a development and sales collaboration with Merck & Co., Inc. and AstraZeneca UK Limited to develop anti-cancer drugs. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

DAIICHI SANKYO COMPANY LIMITED News
10:10 AM ENHERTU gains conditional approval in China to treat NSCLC
10/01/24 AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
10/01/24 ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy
09/24/24 AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal
09/23/24 AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
09/23/24 Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
09/23/24 AstraZeneca and Daiichi Sankyo report data from Phase III breast cancer trial
09/23/24 Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
09/20/24 NHS England to offer Daiichi Sankyo’s quizartinib for AML
09/18/24 Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
09/18/24 Daiichi Sankyo and MSD’s ADC improves progression-free survival in NSCLC trial
09/17/24 Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
09/17/24 ADC developed by Daiichi, Merck outperforms chemo in lung cancer trial
09/17/24 Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
09/16/24 Daiichi Sankyo posts positive DS-9606 clinical trial results in solid tumours
09/15/24 DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors
09/13/24 AstraZeneca, Daiichi Sankyo Breast Cancer Drug Trial Shows 'Substantial Clinical Activity'
09/13/24 ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases
09/10/24 AstraZeneca/Daiichi’s ADC shows better survival for nonsquamous NSCLC patients
09/10/24 AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
DSNKY Chatroom

User Image YoloAlfred Posted - 3 days ago

$DSNKY 🤫🤫🤫🤫

User Image PenkeTrading Posted - 09/24/24

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Daiichi Sankyo Co Ltd ADR. Is that bullish or bearish? $DSNKY #RsiOversold #PINK

User Image aless12 Posted - 1 month ago

$DSNKY Pay attention to $ADCT

User Image SparkyReturns Posted - 08/22/24

$TAK Check out XERS for another biotech investing idea. Their high-concentration Sub-Q delivery tech can be used with MANY drugs currently being delivered by IV by your company, especially MAbs. XERS already has collabs with big pharma REGN, AMGN, and Beta Bionics. AMGN even ditched HALO recently to go with XERS delivery system instead for Tepezza because higher concentrations and no need for refrigeration. Why am I so optimistic? 1. Stable and growing revenue base of 3 products. 2. SubQ Levo (XP-8121 thyroid treatment) will solve administration issues for people with gastro issues/pills, $2-3B TAM. XERS has hinted about bringing on a partner to monetize value. 3. Will hear soon on collabs with Amgen, Regeneron, and Beta Bionics and will learn soon what the terms are of their upfront payments and milestone payments. 4. Tutes have been quietly loading up, highest institutional ownership ever. How do you like the chart?! Cheers! $DSNKY $ILMN $ALXN $SGEN

User Image Rustyton Posted - 2 months ago

$ESPR Meanwhile, $DSNKY has gone from $30 to $40 in recent months

User Image PenkeTrading Posted - 2 months ago

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Daiichi Sankyo Co Ltd ADR. Is that bullish or bearish? $DSNKY #DSNKY #pink #tradingsignals #technicalanalysis

User Image HemaFL24 Posted - 07/31/24

$DSNKY called it! Above $40 🚀

User Image HemaFL24 Posted - 07/16/24

$DSNKY lets go $40+🚀🚀

User Image Rescueoncredit Posted - 3 months ago

$DSNKY soon they will buy Esperion therapeutics.

User Image Greedy_AF Posted - 06/29/24

$DSNKY this very bad stocks just failed! now must to hari kari https://finance.yahoo.com/m/ac27174d-24b9-3065-bb61-b5c58631159a/dow-jones-powerhouse-merck.html

User Image DonCorleone77 Posted - 05/30/24

$CGEN $AZN $DSNKY Compugen to receive $5M milestone payment from AstraZeneca Compugen (CGEN) is entitled to receive a $5M milestone payment from AstraZeneca (AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody. The TIGIT component of rilvegostomig is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. The trial is evaluating the efficacy and safety of rilvegostomig as monotherapy and in combination with datopotamab deruxtecan, AstraZeneca and Daiichi Sankyo's (DSNKY) TROP2-directed antibody drug conjugate versus pembrolizumab as first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations. The trial is sponsored by AstraZeneca in collaboration with Daiichi Sankyo. The ARTEMIDE-Biliary01 Phase 3 trial is evaluating the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in patients with biliary tract cancer after surgical resection with curative intent.

User Image Broview Posted - 5 months ago

$DSNKY low key but with promising oncology portfolio?

User Image DonCorleone77 Posted - 6 months ago

$AZN $DSNKY 2 of 2 - ENHERTU approved for treatment of unresectable or metastatic HER2 positive ....The first tumor agnostic approval of a HER2 directed therapy and ADC was based on efficacy data in 192 adult patients with previously treated unresectable or metastatic HER2 positive solid tumors who were enrolled in one of three multicenter phase 2 trials from the DESTINY clinical development program, including DESTINY-PanTumor02, DESTINY-Lung01 or DESTINY-CRC02. The major efficacy outcome measure in all three of the studies was confirmed ORR and an additional efficacy outcome measure was DOR. ENHERTU is approved with Boxed WARNINGS for interstitial lung disease/pneumonitis and Embryo-Fetal toxicity.

User Image DonCorleone77 Posted - 6 months ago

$AZN $DSNKY 1 of 2 - ENHERTU approved for treatment of unresectable or metastatic HER2 positive Daiichi Sankyo (DSNKY) and AstraZeneca's (AZN) ENHERTU has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ENHERTU is a specifically engineered HER2 directed antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca....

User Image NEWBIGTECH Posted - 03/18/24

$ESPR Maybe call the company , and $DSNKY TO keep everyone in the loop. I am sure they would want to also know why the stock is manipulated, or at least seems to be.

User Image NEWBIGTECH Posted - 03/16/24

$ESPR $DSNKY , I agree, management with ESPR are not doing everything possible to bring the stock price up, or protect the company. I have called and left messages with the company to no avail. That is why I also add the SEC in all correspondence.

User Image NEWBIGTECH Posted - 03/16/24

$ESPR GSA Capital Partners LLP Has $1.09 Million Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) A number of analysts have issued reports on ESPR shares. HC Wainwright cut their price objective on shares of Esperion Therapeutics from $22.00 to $16.00 and set a "buy" rating for the company in a report . $PFE $JNJ #AMGN $DSNKY

User Image YoloAlfred Posted - 8 months ago

$ESPR add $DSNKY to your watchlist

User Image YoloAlfred Posted - 01/31/24

$ESPR I had ticker $DSNKY added this morning. .....put it on your watchlist (our partner in EU)

User Image YoloAlfred Posted - 01/31/24

$DSNKY

User Image YoloAlfred Posted - 01/31/24

$DSNKY OK ESPR CLUB.....add this to your watchlist to follow our partner in Europe